Summit Therapeutics (NASDAQ:SMMT - Get Free Report) is expected to post its Q1 2025 quarterly earnings results on Tuesday, April 29th. Analysts expect Summit Therapeutics to post earnings of ($0.07) per share for the quarter.
Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The business had revenue of $0.20 million during the quarter. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Summit Therapeutics Stock Performance
Shares of NASDAQ:SMMT traded down $13.23 during trading hours on Friday, hitting $23.47. 24,583,288 shares of the company's stock traded hands, compared to its average volume of 3,763,031. The company's fifty day simple moving average is $20.90 and its two-hundred day simple moving average is $20.10. The company has a market cap of $17.31 billion, a price-to-earnings ratio of -83.82 and a beta of -0.46. Summit Therapeutics has a 52 week low of $2.10 and a 52 week high of $36.91.
Analyst Ratings Changes
Several research firms have issued reports on SMMT. The Goldman Sachs Group started coverage on Summit Therapeutics in a report on Friday, February 28th. They issued a "buy" rating and a $42.00 price target on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Summit Therapeutics in a report on Wednesday. Jefferies Financial Group set a $44.00 price target on Summit Therapeutics and gave the stock a "buy" rating in a research note on Friday. Truist Financial assumed coverage on shares of Summit Therapeutics in a research note on Wednesday, January 8th. They set a "buy" rating and a $35.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $44.00 price target on shares of Summit Therapeutics in a research report on Tuesday, February 25th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $36.70.
View Our Latest Analysis on SMMT
Summit Therapeutics Company Profile
(
Get Free Report)
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Featured Stories
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
